Daily Roundup

DDR.ASX CSX.ASX 4DX.ASX PXA.ASX SEQ.ASX

Dicker Data is riding high on strong momentum, reporting half-year results that paint a picture of robust growth across the board. The tech distributor's gross revenue climbed 14.2% to $2.1 billion, while gross profit jumped 23% to $205.6 million. What's particularly impressive is the margin expansion—gross profit margin improved to 9.8%, and EBITDA surged 37.3% to $103.5 million. Net profit before tax nearly doubled, rising 50.1% to $86.4 million. The company's confidence is reflected in its full-year guidance, which forecasts gross revenue between $4.3 billion and $4.4 billion, with net operating profit before tax between $162 million and $165 million. Shareholders are also being rewarded with a fully franked dividend of 23.0 cents per share, up 4.5% from the prior year. Management expects favourable conditions to persist through the second half, driven by technology refresh cycles, AI infrastructure investments, and sustained software demand—though they're keeping an eye on potential pricing pressures from supply chain constraints.

4DMedical is celebrating a major milestone with FDA clearance for its CT:VQ technology, a breakthrough that opens significant commercial opportunities in the U.S. market. The company reported 21% revenue growth to $7.1 million for the full year, with impressive gross margins exceeding 90%. Beyond the U.S., CT:VQ has now been authorized across six jurisdictions including the European Union, United Kingdom, Canada, New Zealand, and Australia. The technology has already gained traction with top U.S. Academic Medical Centers and secured Medicare reimbursement at US$650.50 per scan. Notably, CT:VQ demonstrated its clinical value in lung volume reduction surgery, with responder rates jumping from 46% to 76%. The company is also building strategic partnerships with pharmaceutical giants AstraZeneca and GlaxoSmithKline to support lung health screening programs and drug development. Despite the commercial progress, 4DMedical reported an adjusted net loss of $32.9 million for the year, though this represents a 7% improvement from the prior year.

CleanSpace Holdings is charting a steady course with its respiratory protection business. Revenue came in at $19.8 million, essentially flat compared to the prior year, but the company maintained strong gross margins of 75%. The real excitement lies in the launch of AGILE, a next-generation loose-fitting powered air purifying respirator that's now available in Europe and the ANZ region. This new product positions CleanSpace to capitalize on tightening regulatory standards globally. The company finished the year with $10.1 million in cash and announced a 10% on-market share buyback, signalling confidence in its value. While Europe drove growth with strong performance in Western Europe and the Nordics, North America and Asia-Pacific faced tougher conditions. Management remains optimistic, targeting compound annual revenue growth of 20% or more over the medium term.

PEXA Group delivered solid results with revenue from continuing operations up 7.2% to $27.4 million and a net profit after tax of $84.8 million. On a broader group basis, revenue climbed 7% to $406.9 million with EBITDA rising 12% to $151.7 million. The company's EBITDA margin improved by 1.7 percentage points to 37.3%, reflecting disciplined cost management. A key highlight was the successful implementation of NatWest's digital remortgage capability in the UK, delivered ahead of schedule. PEXA also launched PEXA Clear, a new AML/CTF compliance platform designed to help Australian real estate professionals meet expanded AUSTRAC obligations. The company strengthened its balance sheet significantly, reducing leverage to 1.0 times. Looking ahead, PEXA is preparing for a New Zealand pilot launch in October 2026 while continuing to engage with Australian regulators on pricing matters. For FY27, the company is guiding for revenue between $385 million and $415 million, with EBITDA margin between 31.5% and 33.5%.

Sequoia Financial Group faced a challenging year, with revenue declining 15% to $105.4 million and a statutory loss after tax of $8.6 million, a sharp reversal from the prior year's $3.2 million profit. Operating profit fell to $4.4 million from $9.8 million, primarily due to lower commission revenue in its InterPrac Financial Planning business. The company revoked its interim dividend and declared no final dividend for the year. Sequoia is navigating several legal headwinds, including proceedings by ASIC and a dispute with the Australian Financial Complaints Authority. The company maintained a sound capital position with $1.6 million in cash and $14.4 million in listed equities, but the path forward requires stabilizing the InterPrac business and resolving ongoing legal challenges.